Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 1667

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1A
Chunk 1667
---
otechnology
and pharmaceutical companies can be highly uncertain and involve complex legal and factual questions for which important legal principles
remain unresolved. No consistent policy regarding the breadth of claims allowed in pharmaceutical patents has emerged to date in the United
States or in many jurisdictions outside of the United States. Changes in either the patent laws or interpretations of patent laws in the
United States and other countries may diminish the value of our owned or licensed intellectual property. Accordingly, we cannot predict
the breadth of claims that may be enforced in the patents that may be issued from the applications we currently or may in the future own
or license from third parties. Further, if any patents we obtain or license are deemed invalid or unenforceable, our ability to commercialize
or license our technology could be adversely affected.

Others have filed, and in
the future are likely to file, patent applications covering products and technologies that are similar, identical or competitive to ours
or important to our business. We cannot be certain that any patent application owned by a third party will not have priority over patent
applications filed or in-licensed by us, or that we will not be involved in interference, opposition or invalidity proceedings before
U.S. or non-U.S. patent offices.

The degree of future protection
for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or
permit us to gain or keep our competitive advantage. For example:

●others may be able to make product candidates or develop a platform similar to, or better than, ours in
a way that is not covered by the claims of our licensed or owned patents;

●others may be able to make compounds that are similar to our product candidates but that are not covered
by the claims of patents we own or that are licensed to us;

●we or our prospective licensors or future collaborators might not have been the first to make the inventions
covered by any pending patent applications issued patents that we own or license;

●we or our prospective licensors or future collaborators might not have been (or may not be in the future)
the first to file patent applications for certain of our inventions;

●others may independently develop similar or alternative technologies or duplicate any of our technologies
without infringing our intellectual property rights;

●our pending patent applications may not lead to issued patents;

●issued patents that we own or license may be held invalid or unenforceable as a result of legal challenges
by our competitors or others;

●our competitors might conduct R&D activities in countries where